ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0567

N-Terminal Pro-Brain Natriuretic Peptide Correlates Strongly with Cardiovascular Damage in Systemic Lupus Erythematous (SLE): A Cross-sectional Study

(0543–0581) SLE – Diagnosis, Manifestations, & Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0610

Nailfold Capillaroscopy for Prediction of Novel Severe Organ Involvement in Systemic Sclerosis

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0623

Nailfold Capillaroscopy in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) Treated with Nintedanib

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0300

Nailfold Videocapillaroscopy in Idiopathic Inflammatory Myopathy Compared with Healthy Controls

(0283–0307) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0351

Needs Assessment Survey of Critical Data Element Completion in Telemedicine Visits for Juvenile Idiopathic Arthritis in the Post-Pandemic Period

(0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-11:00AM: Abstract Number: 0629

Negative Affect, Anxiety and Fatigue Moderate the Association Between Pain Intensity and Physical Function in People with Systemic Sclerosis

(0609–0672) Systemic Sclerosis & Related Disorders – Clinical Poster I: Research

9:00AM-11:00AM: Abstract Number: 0110

Neutrophil Extracellular Traps as Mediators of Antiphospholipid Antibody-Induced Trophoblast Dysfunction and Fetal Loss

(0096–0116) Antiphospholipid Syndrome Poster

9:00AM-11:00AM: Abstract Number: 0037

New Histological Approach in Spatial Transcriptomics Implicates Glandular Cell Involvement in Pathophysiology of Sjögren’s Disease

(0013–0039.5) Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: 0142

New-Onset Systemic Autoimmune Diseases Following COVID-19 Vaccination – Results from the COVAD Study

(0117–0144) Epidemiology & Public Health Poster I

9:00AM-11:00AM: Abstract Number: 0708

NFKB1 and NFKBIA: Relevant Players in the Pathogenesis of IgA Vasculitis?

(0691–0721) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

9:00AM-11:00AM: Abstract Number: 0053

Nintedanib Downregulates the Profibrotic M2 Phenotype of Macrophages Obtained from Systemic Sclerosis Patients Affected by Interstitial Lung Disease

(0040–0064) Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 0256

Nintedanib in Combination with Immunosuppressive Agents Improves Forced Vital Capacity in Connective Tissue Disease-associated PF-ILD: A Single-center Study

(0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 0419

No Clinically Relevant Changes in Coagulation Activation Between Patients Initiating TNF-blockers versus JAK-inhibitors

(0380–0422) RA – Diagnosis, Manifestations, and Outcomes Poster I

9:00AM-11:00AM: Abstract Number: 0275

No Cumulative Effect of Infection Rates in Children Receiving Long-term Canakinumab Treatment in Autoinflammatory Periodic Fever Syndromes − Data from the RELIANCE Registry

(0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 0278

NOD2 Genotyping Landscape in Yao Syndrome

(0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].